Victoria has reclaimed its position as the leading state for SAS-B medicinal cannabis approvals, overtaking Queensland in February as the Therapeutic Goods Administration cleared 12,301 applications — a 16% increase on the previous month.
The state accounted for 5,168 approvals during the period, edging out Queensland's 3,965. New South Wales held third place, as it has in prior months, with 2,601 approvals.
High-THC, category 5 medicines accounted for nearly half of all approvals at 6,057, with 43% of those — or 2,598 — going to men between the ages of 18 and 44.
Across all categories, men outnumbered women by a 60:40 margin.
Chronic pain, anxiety, and sleep disorders were the conditions most frequently cited in approved SAS-B applications, with depression, PTSD, and ADHD also featuring prominently.
Oral solutions continued to lead on delivery format, making up 47% of approvals. Flower came second at 37%, followed by inhalation at 8%, while pastilles took fourth place with 3%, displacing capsules from that position.
The 12,301 applications were submitted by a total of 906 prescribers.
